NA
SCMP

Navellier & Associates’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Navellier & Associates’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-24,735
Closed -$428K – 304
2015
Q4 		$428K Sell
24,735
-11,323
-31% -$203K 0.05% 136
2015
Q3 		$716K Sell
36,058
-59,874
-62% -$1.37M 0.07% 114
2015
Q2 		$1.58M Buy
95,932
+75,663
+373% +$1.31M 0.14% 83
2015
Q1 		$315K Buy
+20,269
New +$314K 0.03% 272

Other funds holding SCMP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Navellier & Associates's SCMP Position: Q1 2016 in Review

Navellier & Associates sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2016, closing a stake of 24,735 shares — an estimated $428K sold.

Navellier & Associates first reported a position in SCMP in Q1 2015 and held it in 4 quarters. The position peaked at $1.58M in Q2 2015. 134 funds tracked by Wall St. Rank hold SCMP as of Q1 2016.

  • Navellier & Associates reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Navellier & Associates sold 24,735 Sucampo Pharmaceuticals, Inc. shares in Q1 2016, an estimated $428K.
  • Navellier & Associates first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2015 and held it in 4 quarters.
  • Navellier & Associates's Sucampo Pharmaceuticals, Inc. position peaked at $1.58M in Q2 2015.
  • 134 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2016.

Based on Navellier & Associates's 13F filing for Q1 2016, filed 13 May 2016.